Several meta-analyses have been performed to study KRAS and BRAF mutations in melanoma (56), non-small cell lung cancer (NSCLC) (57), colorectal cancer (58,59) and papillary thyroid cancer (60). This evidence concerns the gene KRAS and thyroid gland papillary carcinoma.